Kazia Therapeutics Limited Stock Prediction and Forecast [KZIA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 19 Nov 2025, 04:00 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Kazia Therapeutics Limited Stock Prediction and Forecast [KZIA]](https://i.ytimg.com/vi/jaf86WjjNvM/hqdefault.jpg)
AI-generated source summary
Kazia Therapeutics Limited is assessed as a strong sell candidate, achieving a score of -7.125 on Tuesday, November 18, 2025. The stock has demonstrated a negative performance, with an 8.13% loss over the preceding three days, equating to an average daily decline of 2.71%. The price has broken through a wide and declining short-term trend, indicating a realistic potential for further depreciation. Technical analysis, incorporating 'fan theory', identifies a new lower boundary at $4.06, suggesting this as a potential target. The current three-month trend forecasts a decrease of approximately 10.39%. Additionally, a longer-term 12-month analysis projects a 42.17% decline, situating the future price within a range of $0.00 to $5.23. The stock closed at $5.76 on the last trading day, having fallen 5.29% that day and 24.8% over the past ten days. An increase in trading volume amidst falling prices is noted as an early warning signal. The company's price-to-earnings ratio is negative at -0.325, signifying losses and raising concerns regarding profitability and potential bankruptcy risks. Identified resistance levels for the stock are at $6.04, $6.20, $6.31, $6.37, $6.86, and $7.10, with no significant support found from accumulated volume below the current price. While a general sell signal is derived from the moving averages and MACD, some contradictory buy signals are present from Bollinger Bands and specific moving average crosses. The overall outlook for Kazia Therapeutics is negative, characterized by high volatility and elevated risk.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.